Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

Overview

Genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in Korean population have been increased due to the aged population and the westernized lifestyles. With the advancement of technologies, studies have found that microbiome not only affects human physiological functions, such as metabolism, immunity, and haematopoiesis, but also plays a significant role in the development and progression of malignancies. However, the investigation of microbiome in urological malignances have been limited and few studies have been reported. Therefore, the investigator tried to evaluate the usefulness of microbiome in detection and monitoring of urological malignancies in Korean population. This study aims to use microbiome in tissue, plasma, stool and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. This study plan includes building big databases for microbiome of urological malignancies in Korean population.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2030

Arms, Groups and Cohorts

  • Prostate cancer
    • Patients diagnosed as prostate cancer and have undergone prostatectomy
  • Renal cell cancer
    • Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
  • Bladder cancer
    • Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
  • Ureter cancer
    • Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy

Clinical Trial Outcome Measures

Primary Measures

  • Correlation between tissue bacteria composition and prevalence of urological malignancies
    • Time Frame: within 2 weeks after the surgery
    • evaluate and compare the bacteria composition in tissue samples in urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) with healthy control group
  • Correlation between plasma bacteria composition and prevalence of urological malignancies
    • Time Frame: within 2 weeks after the surgery
    • evaluate and compare the bacteria composition in plasma samples in urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) with healthy control group
  • Correlation between stool bacteria composition and prevalence of urological malignancies
    • Time Frame: within 2 weeks after the surgery
    • evaluate and compare the bacteria composition in stool samples in urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) with healthy control group
  • Correlation between urine bacteria composition and prevalence of urological malignancies
    • Time Frame: within 2 weeks after the surgery
    • evaluate and compare the bacteria composition in urine samples in urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) with healthy control group

Secondary Measures

  • Correlation of bacteria composition and tumor response assessed using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
    • Time Frame: within 10 years after the surgery
    • Association between bacteria composition and oncological prognosis, progression, and therapeutic response in urological malignancies

Participating in This Clinical Trial

Inclusion Criteria

  • Patients diagnosed as urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) – Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2020.10 and 2030.10 – Those who agree to give permission to use their human source information – Those who agree with this study Exclusion Criteria:

  • Those who do not agree with this study – Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Yonsei University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Won Sik Ham, Principal Investigator, Severance Hospital
  • Overall Contact(s)
    • Won Sik Ham, 82-02-2228-2310, uroham@yuhs.ac

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.